Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 5/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 4/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.31 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16094155 | 1.00 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2CYP2D6CYP2C19LMNA | |
| SCHEMBL5830226 | 0.88 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2CYP2D6CYP2C19LMNA | |
| SCHEMBL2739998 | 0.81 | CYP2D6 (0.61) | ALDH1A1CYP2D6CYP2C19LMNAATM | |
| SCHEMBL28707499 | 0.81 | CYP2D6 (0.61) | ALDH1A1CYP2D6CYP2C19LMNAATM | |
| SCHEMBL3486081 | 0.76 | — | — | |
| SCHEMBL20818221 | 0.75 | CA2 (0.45) | CYP2D6KMT2AMEN1 | |
| SCHEMBL20818224 | 0.75 | CA2 (0.45) | CYP2D6KMT2AMEN1 | |
| SCHEMBL20605829 | 0.74 | — | — | |
| SCHEMBL18758356 | 0.74 | — | — | |
| SCHEMBL3578313 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | PDXK, ATP6V1B1, REN | ALDH1A1 649/4885SMN1; SMN2 2435/4885CYP2D6 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.